[Drug therapy of hyperprolactinemia, acromegaly and Cushing syndrome].
39 patients with hyperprolactinaemia (32 adenomas of the pituitary gland, 7 idiopathic hyperprolactinaemias) were treated with the ergot derivative Lisurid. In 3 patients side-effects appeared which did not allow an increase to the therapy-effective dose. In all other patients with a dose of 0.075 to 6 mg Lisurid a day a normalisation of the prolactinaemia was achieved. A pregnancy appeared in 15 of 16 women who wished a child. In 4 men with normal gonadotropic reserve libido, potency and plasma testosterone normalised after the treatment with Lisurid. In addition of Lisurid also other ergot derivatives with prolactin-inhibiting effect, such as dironyl, deprenone and propyldeprenone were tested. Here dironyl has an advantage showing less side-effects and no changes of blood pressure. The ergot derivatives may be used also in the treatment of acromegaly. In 7 of 21 patients with acromegaly who were treated a longer time we succeeded in reducing the level of the growth hormone below 50%, in 2 patients the condition completely normalised. On the other hand, a normalisation of the somatomedin level appeared only in 11 of 21 patients. Patients with central Cushing's disease only exceptionally react to the treatment with ergot derivatives.
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003480:Cushing Syndrome / Q000188:drug therapy*; D004873:Ergolines / Q000627:therapeutic use*; D004879:Ergotamines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008090:Lisuride / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011388:Prolactin / Q000097:blood*
D004873:Ergolines; D004879:Ergotamines; D011388:Prolactin; D008090:Lisuride
Medikamentöse Behandlung der Hyperprolaktinämie, Akromegalie und Cushing-Krankheit.